vs
Offerpad Solutions Inc.（OPAD）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Offerpad Solutions Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.6倍（$114.1M vs $69.8M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -34.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -36.8%）
Offerpad Solutions Inc是美国知名房地产科技企业，专注于简化住宅房产交易流程，采用iBuyer模式直接向卖家收购房屋，完成翻新后挂牌出售，同时提供按揭、产权服务、灵活搬迁方案等配套服务，业务覆盖美国数十个州。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
OPAD vs RIGL — 直观对比
营收规模更大
OPAD
是对方的1.6倍
$69.8M
营收增速更快
RIGL
高出55.7%
-34.5%
两年增速更快
RIGL
近两年复合增速
-36.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 7.0% | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -34.5% | 21.2% |
| 净利润同比 | 49.1% | 1769.2% |
| 每股收益（稀释后） | — | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPADRIGL
| Q4 25 | $114.1M | $69.8M | ||
| Q3 25 | $132.7M | $69.5M | ||
| Q2 25 | $160.3M | $101.7M | ||
| Q1 25 | $160.7M | $53.3M | ||
| Q4 24 | $174.3M | $57.6M | ||
| Q3 24 | $208.1M | $55.3M | ||
| Q2 24 | $251.1M | $36.8M | ||
| Q1 24 | $285.4M | $29.5M |
净利润OPADRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-11.6M | $27.9M | ||
| Q2 25 | $-10.9M | $59.6M | ||
| Q1 25 | $-15.1M | $11.4M | ||
| Q4 24 | $-17.3M | $14.3M | ||
| Q3 24 | $-13.5M | $12.4M | ||
| Q2 24 | $-13.8M | $-1.0M | ||
| Q1 24 | $-17.5M | $-8.2M |
毛利率OPADRIGL
| Q4 25 | 7.0% | 91.5% | ||
| Q3 25 | 7.0% | 93.2% | ||
| Q2 25 | 8.9% | 95.6% | ||
| Q1 25 | 6.5% | 91.7% | ||
| Q4 24 | 6.1% | 89.9% | ||
| Q3 24 | 8.2% | 85.5% | ||
| Q2 24 | 8.7% | 92.4% | ||
| Q1 24 | 7.9% | 93.1% |
营业利润率OPADRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | -5.1% | 40.9% | ||
| Q2 25 | -4.9% | 60.1% | ||
| Q1 25 | -7.2% | 23.9% | ||
| Q4 24 | -7.8% | 28.9% | ||
| Q3 24 | -4.3% | 25.4% | ||
| Q2 24 | -3.9% | 1.2% | ||
| Q1 24 | -4.8% | -23.6% |
净利率OPADRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -8.7% | 40.2% | ||
| Q2 25 | -6.8% | 58.6% | ||
| Q1 25 | -9.4% | 21.5% | ||
| Q4 24 | -9.9% | 24.9% | ||
| Q3 24 | -6.5% | 22.5% | ||
| Q2 24 | -5.5% | -2.8% | ||
| Q1 24 | -6.1% | -27.9% |
每股收益（稀释后）OPADRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | $-0.37 | $1.46 | ||
| Q2 25 | $-0.39 | $3.28 | ||
| Q1 25 | $-0.55 | $0.63 | ||
| Q4 24 | $-0.64 | $0.82 | ||
| Q3 24 | $-0.49 | $0.70 | ||
| Q2 24 | $-0.50 | $-0.06 | ||
| Q1 24 | $-0.64 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.5M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $38.2M | $391.5M |
| 总资产 | $154.8M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资OPADRIGL
| Q4 25 | $26.5M | $155.0M | ||
| Q3 25 | $31.0M | $137.1M | ||
| Q2 25 | $22.6M | $108.4M | ||
| Q1 25 | $30.8M | $77.1M | ||
| Q4 24 | $43.0M | $77.3M | ||
| Q3 24 | $48.5M | $61.1M | ||
| Q2 24 | $56.9M | $49.1M | ||
| Q1 24 | $68.5M | $49.5M |
总债务OPADRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益OPADRIGL
| Q4 25 | $38.2M | $391.5M | ||
| Q3 25 | $39.9M | $117.6M | ||
| Q2 25 | $24.5M | $81.9M | ||
| Q1 25 | $34.2M | $18.6M | ||
| Q4 24 | $47.7M | $3.3M | ||
| Q3 24 | $64.7M | $-14.6M | ||
| Q2 24 | $77.6M | $-29.9M | ||
| Q1 24 | $88.1M | $-31.7M |
总资产OPADRIGL
| Q4 25 | $154.8M | $513.6M | ||
| Q3 25 | $223.5M | $242.5M | ||
| Q2 25 | $268.0M | $206.7M | ||
| Q1 25 | $274.5M | $176.0M | ||
| Q4 24 | $313.1M | $164.0M | ||
| Q3 24 | $338.5M | $139.4M | ||
| Q2 24 | $406.6M | $128.4M | ||
| Q1 24 | $369.7M | $126.5M |
负债/权益比OPADRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.8M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $65.7M | — |
| 自由现金流率自由现金流/营收 | 57.6% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流OPADRIGL
| Q4 25 | $66.8M | $22.0M | ||
| Q3 25 | $40.0M | $24.0M | ||
| Q2 25 | $-13.5M | $30.5M | ||
| Q1 25 | $-10.2M | $-893.0K | ||
| Q4 24 | $20.8M | $14.5M | ||
| Q3 24 | $39.6M | $21.7M | ||
| Q2 24 | $-54.4M | $302.0K | ||
| Q1 24 | $2.4M | $-5.0M |
自由现金流OPADRIGL
| Q4 25 | $65.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $-11.2M | — | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $38.7M | — | ||
| Q2 24 | $-54.4M | — | ||
| Q1 24 | $2.0M | — |
自由现金流率OPADRIGL
| Q4 25 | 57.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.5% | — | ||
| Q1 25 | -7.0% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | -21.7% | — | ||
| Q1 24 | 0.7% | — |
资本支出强度OPADRIGL
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
现金转化率OPADRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
